Slovenia R&D and Manufacturing Site
It is the first CDMO-type company in the pharmaceutical industry in Slovenia, dedicated to providing comprehensive services to customers, encompassing synthesis route development, process familiarization, analytical method development and validation, and process scale-up.
Kolodvorska cesta 27, 1234 Mengeš
2023Founded
R&D and kilo-labs have been put into operation, and construction of the pilot plant has also started. The facility is equipped with advanced process development and analysis equipment, as well as a complete project operation team.
25000m2Total Factory
An integrated and production-oriented R&D team, driven by the right-first-time philosophy at scale, features process scale-up experts, chemical engineers, and analytical chemists.
R&D Capabilities
- Pressure Reactions (hydrogenation, Carbonylation, etc.)
- Cryogenic - High Temperature Reactions (-80 to 200 °C)
- Enzymatic Reactions and Biocatalysis
- Organometallic Chemistry (Grignard, RLi, etc.)
- Protective Groups Handling
- Homogeneous and Heterogeneous Catalysis
- Precious Metals Catalysis (cross-couplings, etc.)
- Special/Hazardous Reagents (borane, cyanides, dimethyl sulfate, chlorine, bromine, triphosgene, etc.)
- Stereoselective Synthesis and Chiral Resolution
Services
Small Molecule
Small Molecule
Porton offers efficient, flexible, and high-quality solutions for custom development and production of small molecule APIs, as well as technical services throughout the entire lifecycle from pre-clinical to commercial stages to our worldwide partners.
One Porton One Quality
Compliance standards, Continuous improvement, Customer oriented
Quality management runs throughout the entire process of the drug life cycle. The quality management system of the drug product site is built in accordance with international standards and continues to adhere to the quality concept of 'more well-established system, more controllable quality.' This ensures that the GMP activities of the drug product site meet the requirements of international quality management systems and market drug regulatory agencies, including those of China, the European Union, FDA, and other mainstream regulations.
